Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes

AC Howlett

The inhibition of adenylate cyclase activity by cannabimimetic compounds in a membrane fraction from cultured neuroblastoma cells has been examined. The inhibition was shown to be concentration-dependent over a nanomolar range for both delta 9-tetrahydrocannabinol and its synthetic analog, desacetyllevonantradol. Inhibition was rapid and reversible. The cannabimimetic compounds caused a decrease in Vmax of the enzyme, with no alteration in the Km for substrate. The effects of these compounds were related to the ability of the enzyme to be regulated by divalent cations and guanine nucleotides. The inhibition was greatest at micromolar Mg2+ or Mn2+ concentrations and was abolished at less than 1 mM MnCl2. In the hormone-stimulated state, the enzyme appeared to be regulated by one Mg2+ site. The addition of cannabimimetic or muscarinic cholinergic agents transformed the enzyme into one in which more complex regulation by divalent cations was observed. Half-maximal inhibition of adenylate cyclase was observed at 800 nM GTP for both cannabimimetic and muscarinic cholinergic agents. The substitution for GTP of a nonhydrolyzable analog resulted in activation of the enzyme and failure to respond to either class of inhibitory agents. If the Mg2+ concentration was reduced and exposure to the GTP analog was of short duration, inhibition by both cannabimimetic and muscarinic agents could be observed in the presence of forskolin. This study points to the similarities between the enzyme inhibition by cannabimimetic compounds and by muscarinic cholinergic compounds. It is inferred that the cannabimimetic compounds must act via regulatory mechanisms similar to those operating for receptor- mediated inhibition of adenylate cyclase.

Volume 27, Issue 4, pp. 429-436, 04/01/1985
Copyright © 1985 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				J. L. Niehaus, Y. Liu, K. T. Wallis, M. Egertova, S. G. Bhartur, S. Mukhopadhyay, S. Shi, H. He, D. E. Selley, A. C. Howlett, et al. CB1 Cannabinoid Receptor Activity Is Modulated by the Cannabinoid Receptor Interacting Protein CRIP 1a Mol. Pharmacol., December 1, 2007; 72(6): 1557 - 1566. [Abstract] [Full Text] [PDF]

				C. Liu and J. M. Walker Effects of a Cannabinoid Agonist on Spinal Nociceptive Neurons in a Rodent Model of Neuropathic Pain J Neurophysiol, December 1, 2006; 96(6): 2984 - 2994. [Abstract] [Full Text] [PDF]

				J. L. Shoemaker, M. B. Ruckle, P. R. Mayeux, and P. L. Prather Agonist-Directed Trafficking of Response by Endocannabinoids Acting at CB2 Receptors J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 828 - 838. [Abstract] [Full Text] [PDF]

				X.-Q. Xie and J.-Z. Chen NMR Structural Comparison of the Cytoplasmic Juxtamembrane Domains of G-protein-coupled CB1 and CB2 Receptors in Membrane Mimetic Dodecylphosphocholine Micelles J. Biol. Chem., February 4, 2005; 280(5): 3605 - 3612. [Abstract] [Full Text] [PDF]

				M. Alberich Jorda, N. Rayman, M. Tas, S. E. Verbakel, N. Battista, K. van Lom, B. Lowenberg, M. Maccarrone, and R. Delwel The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner Blood, July 15, 2004; 104(2): 526 - 534. [Abstract] [Full Text] [PDF]

				H. Daniel, A. Rancillac, and F. Crepel Mechanisms underlying cannabinoid inhibition of presynaptic Ca2+ influx at parallel fibre synapses of the rat cerebellum J. Physiol., May 15, 2004; 557(1): 159 - 174. [Abstract] [Full Text] [PDF]

				M. A. Jorda, B. Lowenberg, and R. Delwel The peripheral cannabinoid receptor Cb2, a novel oncoprotein, induces a reversible block in neutrophilic differentiation Blood, February 15, 2003; 101(4): 1336 - 1343. [Abstract] [Full Text] [PDF]

				R. S. Martin, P. H. Reynen, J. J. Calixto, C. L. Reyes, T. K. Chang, P. S. Dietrich, D. W. Bonhaus, and S. J. Maclennan Pharmacological Comparison of a Recombinant CB1 Cannabinoid Receptor with Its Ga16 Fusion Product J Biomol Screen, June 1, 2002; 7(3): 281 - 289. [Abstract] [PDF]

				J. Nie and D. L. Lewis Structural Domains of the CB1 Cannabinoid Receptor That Contribute to Constitutive Activity and G-Protein Sequestration J. Neurosci., November 15, 2001; 21(22): 8758 - 8764. [Abstract] [Full Text] [PDF]

				J. J. Rodriguez, K. Mackie, and V. M. Pickel Ultrastructural Localization of the CB1 Cannabinoid Receptor in {micro}-Opioid Receptor Patches of the Rat Caudate Putamen Nucleus J. Neurosci., February 1, 2001; 21(3): 823 - 833. [Abstract] [Full Text] [PDF]

				S. S. Yea, K.-H. Yang, and N. E. Kaminski Role of Nuclear Factor of Activated T-Cells and Activator Protein-1 in the Inhibition of Interleukin-2 Gene Transcription by Cannabinol in EL4 T-Cells J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 597 - 605. [Abstract] [Full Text]

				J. P. Roche, S. Bounds, S. Brown, and K. Mackie A Mutation in the Second Transmembrane Region of the CB1 Receptor Selectively Disrupts G Protein Signaling and Prevents Receptor Internalization Mol. Pharmacol., September 1, 1999; 56(3): 611 - 618. [Abstract] [Full Text]

				M. Bouaboula, D. Dussossoy, and P. Casellas Regulation of Peripheral Cannabinoid Receptor CB2 Phosphorylation by the Inverse Agonist SR 144528. IMPLICATIONS FOR RECEPTOR BIOLOGICAL RESPONSES J. Biol. Chem., July 16, 1999; 274(29): 20397 - 20405. [Abstract] [Full Text] [PDF]

				M. McVey, J. Hill, A. Howlett, and C. Klein Adenylyl Cyclase, a Coincidence Detector for Nitric Oxide J. Biol. Chem., July 2, 1999; 274(27): 18887 - 18892. [Abstract] [Full Text] [PDF]

				N. M. Strangman and J. M. Walker Cannabinoid WIN 55,212-2 Inhibits the Activity-Dependent Facilitation of Spinal Nociceptive Responses J Neurophysiol, July 1, 1999; 82(1): 472 - 477. [Abstract] [Full Text] [PDF]

				D. Gebremedhin, A. R. Lange, W. B. Campbell, C. J. Hillard, and D. R. Harder Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current Am J Physiol Heart Circ Physiol, June 1, 1999; 276(6): H2085 - H2093. [Abstract] [Full Text] [PDF]

				M. Bouaboula, N. Desnoyer, P. Carayon, T. Combes, and P. Casellas Gi Protein Modulation Induced by a Selective Inverse Agonist for the Peripheral Cannabinoid Receptor CB2: Implication for Intracellular Signalization Cross-Regulation. Mol. Pharmacol., March 1, 1999; 55(3): 473 - 480. [Abstract] [Full Text]

				D. W. Bonhaus, L. K. Chang, J. Kwan, and G. R. Martin Dual Activation and Inhibition of Adenylyl Cyclase by Cannabinoid Receptor Agonists: Evidence for Agonist-Specific Trafficking of Intracellular Responses J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 884 - 888. [Abstract] [Full Text]

				D. E. Garcia, S. Brown, B. Hille, and K. Mackie Protein Kinase C Disrupts Cannabinoid Actions by Phosphorylation of the CB1 Cannabinoid Receptor J. Neurosci., April 15, 1998; 18(8): 2834 - 2841. [Abstract] [Full Text] [PDF]

				A. C. Howlett, C. Song, B. A. Berglund, G. H. Wilken, and J. J. Pigg Characterization of CB1 Cannabinoid Receptors Using Receptor Peptide Fragments and Site-Directed Antibodies Mol. Pharmacol., March 1, 1998; 53(3): 504 - 510. [Abstract] [Full Text]

				F Berrendero, L Garcia-Gil, M. Hernandez, J Romero, M Cebeira, R de Miguel, J. Ramos, and J. Fernandez-Ruiz Localization of mRNA expression and activation of signal transduction mechanisms for cannabinoid receptor in rat brain during fetal development Development, January 8, 1998; 125(16): 3179 - 3188. [Abstract] [PDF]

				C. S. Breivogel, L. J. Sim, and S. R. Childers Regional Differences in Cannabinoid Receptor/G-protein Coupling in Rat Brain J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1632 - 1642. [Abstract] [Full Text]

				M. Bouaboula, S. Perrachon, L. Milligan, X. Canat, M. Rinaldi-Carmona, M. Portier, F. Barth, B. Calandra, F. Pecceu, J. Lupker, et al. A Selective Inverse Agonist for Central Cannabinoid Receptor Inhibits Mitogen-activated Protein Kinase Activation Stimulated by Insulin or Insulin-like Growth Factor 1. EVIDENCE FOR A NEW MODEL OF RECEPTOR/LIGAND INTERACTIONS J. Biol. Chem., August 29, 1997; 272(35): 22330 - 22339. [Abstract] [Full Text] [PDF]

				L. J. Sim, R. E. Hampson, S. A. Deadwyler, and S. R. Childers Effects of Chronic Treatment with Delta 9-Tetrahydrocannabinol on Cannabinoid-Stimulated [35S]GTPgamma S Autoradiography in Rat Brain J. Neurosci., December 15, 1996; 16(24): 8057 - 8066. [Abstract] [Full Text] [PDF]

				R. Condie, A. Herring, W. S. Koh, M. Lee, and N. E. Kaminski Cannabinoid Inhibition of Adenylate Cyclase-mediated Signal Transduction and Interleukin 2 (IL-2) Expression in the Murine T-cell Line, EL4.IL-2 J. Biol. Chem., May 31, 1996; 271(22): 13175 - 13183. [Abstract] [Full Text] [PDF]

				D. Shire, B. Calandra, M. Delpech, X. Dumont, M. Kaghad, Gér. Le Fur, D. Caput, and P. Ferrara Structural Features of the Central Cannabinoid CB1 Receptor Involved in the Binding of the Specific CB1 Antagonist SR 141716A J. Biol. Chem., March 22, 1996; 271(12): 6941 - 6946. [Abstract] [Full Text] [PDF]

				M. Bouaboula, B. Bourrié, M. Rinaldi-Carmona, D. Shire, Gér. L. Fur, and P. Casellas Stimulation of Cannabinoid Receptor CB1 Induces krox-24 Expression in Human Astrocytoma Cells J. Biol. Chem., June 9, 1995; 270(23): 13973 - 13980. [Abstract] [Full Text] [PDF]

				D. L. DeCamp, T. M. Thompson, F. J. de Sauvage, and M. R. Lerner Smoothened Activates Galpha i-mediated Signaling in Frog Melanophores J. Biol. Chem., August 18, 2000; 275(34): 26322 - 26327. [Abstract] [Full Text] [PDF]